Fig. 2

Compound 408 inhibits glycolysis without influencing non-glycolytic acidification in human lung fibroblasts. Glycolysis (a), glycolytic reserve (b), glycolytic capacity (c) and non-glycolytic acidification (d) were determined in WI-38 fibroblasts pre-treated for 24 h with LDH5 inhibitor (Compound 408) and TGF-β1, based on changes in ECAR with 10 mM Glucose, 1.25 μM Oligomycin and 50 mM 2-Deoxyglucose (2-DG) as depicted in Fig. 1a. N = 3